Release Date: 29/01/19 08:20 Summary: Appendix 4C - December 2018 Quarter Statement of Cashflows Price Sensitive: Yes Download Document 54.01KB Download
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status